PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 16, 2026Expert Opinion on Drug Metabolism & Toxicology0 citations

Post-marketing pharmacovigilance of tedizolid: emerging safety signals

View Full Paper
HYHaiping YaoGGGuoping GanZWZhu Wang

Key Points

  • To evaluate emerging safety signals associated with tedizolid and understand their clinical significance.
  • Analysis of post-marketing pharmacovigilance data on tedizolid.
  • Identification of hematologic, hepatic, neuropsychiatric, and gastrointestinal risks.
  • Confirmed hematologic risks related to tedizolid use.
  • Identified additional potential hepatic, neuropsychiatric, and gastrointestinal safety signals.

Abstract

Post-marketing data confirm TED's hematologic risks and reveal additional potential hepatic, neuropsychiatric, and gastrointestinal signals. These findings merit further evaluation and prospective studies to clarify clinical significance, establish causality, and optimize monitoring strategies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yao et al. (2026) studied this question.

synapsesocial.com/papers/69e07d3c2f7e8953b7cbe48chttps://doi.org/10.1080/17425255.2026.2660710
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Incidence of serotonin syndrome in patients receiving tedizolid and concomitant serotonergic agents2024 · 4 citations
  2. 2Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis2025 · 13 citations
  3. 3Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome2018 · 9 citations
  4. 4A Real‐World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database2024 · 10 citations
  5. 5Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials2024 · 6 citations